CN104173620A - Pharmaceutical composition for preventing and treating premature ovarian failure and application thereof - Google Patents
Pharmaceutical composition for preventing and treating premature ovarian failure and application thereof Download PDFInfo
- Publication number
- CN104173620A CN104173620A CN201410415513.9A CN201410415513A CN104173620A CN 104173620 A CN104173620 A CN 104173620A CN 201410415513 A CN201410415513 A CN 201410415513A CN 104173620 A CN104173620 A CN 104173620A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- premature ovarian
- ovarian failure
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a pharmaceutical composition for preventing and treating premature ovarian failure and application thereof. The pharmaceutical composition is prepared by decocting and extracting the following traditional Chinese medicine raw materials in parts by weight: 20-38 parts of Root of Yunnan Supplejack, 15-30 parts of rhizoma curculiginis, 11-18 parts of delavay stephania root, 11-18 parts of all-grass of Scabrous Small-hooked Hedyotis, 8-16 parts of Alangium platanifolium and 8-16 parts of Fewflower Lysionotus Herb. The medicine has an obvious curative effect on a patient suffering from premature ovarian failure, so that the patient can have menses for six times or more within one year, the hormone level restores to be normal, and the uterus and ovary return to normal.
Description
Technical field
The invention belongs to medical technical field, in particular to a kind of medical composition and its use of preventing and treating premature ovarian failure.
Background technology
Premature ovarian failure is a kind of refractory disease being caused by Different types of etiopathogenises, and feature is that former or secondary amenorrhea follow blood Gonadotropin Level to raise and estrogen level reduction.Main clinical manifestation is amenorrhea before 40 years old, the symptom that occurs the perimenopausal syndromes such as infertile, sterile, mood change, paraesthesia, insomnia, hypomnesis, senile vaginitis, genital atrophy, dyspareunia, osteoporosis, its cause of disease has that scholar's research proposition and chromosome mutation, inherited genetic factors, autoimmune function are abnormal, Developmental and Metabolic Disorder, iatrogenic and infective agent etc. are relevant.
Modern medicine is still not clear the pathogenetic understanding of premature ovarian failure, western medical treatment mostly adopts and gives the deficiency of corresponding hormone with added body inner estrogen, because the late result of hormone is poor, side effect is large, and the safety of hormonotherapy, carcinogenecity are still in further conceptual phase, thus itself and be not suitable for the conventional therapy of premature ovarian failure.In recent years, the advantage of Chinese medicine premature ovarian failure displays gradually, becomes the focus of academia research.
Summary of the invention
The object of the invention is to folk prescription among the people to improve, thereby a kind of pharmaceutical composition of preventing and treating premature ovarian failure is provided, this pharmaceutical composition is evident in efficacy, with low cost, toxic and side effects is low.
In order to realize object of the present invention, inventor studies by lot of experiments, has finally obtained following technical scheme:
A kind of pharmaceutical composition of preventing and treating premature ovarian failure, wherein, described pharmaceutical composition is extracted and is prepared from through decocting by the traditional Chinese medicinal material raw materials of following weight portion: duck Tripterygium wilfordii 20-38 part, Rhizoma Curculiginis 15-30 part, XIANHUA Radix Stephaniae Japonicae 11-18 part, to sitting leaf 11-18 part, Radix Alangii 8-16 part, Herba Lysionoti Pauciflori 8-16 part.
Further, object of the present invention can also realize like this: the pharmaceutical composition of described control premature ovarian failure, wherein, described pharmaceutical composition is extracted and is prepared from through decocting by the traditional Chinese medicinal material raw materials of following weight portion: duck Tripterygium wilfordii 25-32 part, Rhizoma Curculiginis 20-24 part, XIANHUA Radix Stephaniae Japonicae 13-15 part, to sitting leaf 13-15 part, Radix Alangii 10-13 part, Herba Lysionoti Pauciflori 10-13 part.
Further, object of the present invention can also realize like this: the pharmaceutical composition of described control premature ovarian failure, wherein, described pharmaceutical composition is extracted and is prepared from through decocting by the traditional Chinese medicinal material raw materials of following weight portion: 28 parts of duck Tripterygium wilfordii, 22 parts of Rhizoma Curculiginises, 14 parts of XIANHUA Radix Stephaniae Japonicaes, to sitting 14 parts, leaf, 12 parts of Radix Alangiis, 12 parts of Herba Lysionoti Paucifloris.
It should be noted that, the source of the traditional Chinese medicinal material raw materials that the present invention adopts is as follows: duck Tripterygium wilfordii is selected the dry Herb of Rhamnaceae plant Berchemia polyphylla wall ex Laws Berchemia polyphylla Wall.ex Laws..Rhizoma Curculiginis is selected the dry rhizome of amrallid Rhizoma Curculiginis Curculigo orchioides Gaertn..XIANHUA Radix Stephaniae Japonicae is selected the dry root of Menispermaceae stephania plant XIANHUA Radix Stephaniae Japonicae Stephania graciliflora Yamamoto.To sitting leaf, claim again Herba Hedyotis scabridae, Herba Alternantherae sessilis etc., select the dry herb of the coarse glochild Auricled Hedyotis Herb of Maguireothamnus speciosus.Radix Alangii is selected the dried leaves of Alangiaceae Alangium plant alangium chinense Alangium chinense (Lour.) Rehd..Herba Lysionoti Pauciflori is selected the dry Herb of Gesneriaceae Lysionotus phytobezoar bracketplant Lysionotus pauciflorus Maxim..
According to the conventional formulation technique of the field of Chinese medicines, the pharmaceutical composition that the present invention prevents and treats premature ovarian failure can be made into oral formulations, comprises oral liquid, tablet, capsule, granule, etc.Wherein, chain reaction in patients with premature ovarian is taken Chinese medicine preparation of the present invention sooner or later respectively once every day, within 3 months, is 1 course for the treatment of, generally need to treat 2 courses for the treatment of.
By a large amount of clinical application researchs, find, Chinese medicinal formulae of the present invention has the curative effect of highly significant to the patient of premature ovarian failure, can make patient in 1 year menstrual onset 6 times or more than, it is normal that hormonal readiness recovers, it is normal that uterus and ovary recover.Therefore, another object of the present invention is to provide the pharmaceutical applications of this Chinese medicinal formulae, that is: the purposes of above-mentioned traditional Chinese medicinal material raw materials compositions in the medicine of preparation prevention premature ovarian failure.
Compared with prior art, the pharmaceutical composition tool the present invention relates to has the following advantages and is significant progressive: (1) is evident in efficacy, and prognosis is better.Medicine of the present invention has the curative effect of highly significant to chain reaction in patients with premature ovarian, can make patient in 1 year menstrual onset 6 times or more than, it is normal that hormonal readiness recovers, it is normal that uterus and ovary recover.(2) cost is few, safe.Because medicine of the present invention adopts Chinese medicine material, be prepared from, toxicity is low, and medicine cost is low, and patient spends few, and medication is simultaneously safer.
The specific embodiment
Be below specific embodiments of the invention, technical scheme of the present invention is done to further description, but protection scope of the present invention is not limited to these embodiment.Every do not deviate from the change of the present invention design or be equal to substitute include within protection scope of the present invention.
Embodiment 1
Take duck Tripterygium wilfordii 0.28kg, Rhizoma Curculiginis 0.22kg, XIANHUA Radix Stephaniae Japonicae 0.14kg, to sitting leaf 0.14kg, Radix Alangii 0.12kg and Herba Lysionoti Pauciflori 0.12kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added to water and cover powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 10 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 8 times of amounts of medical material, decoct 1h, get twice decocting liquid and merge, filter the concentrated solution that while being concentrated into 90 ℃, relative density is 1.15; Concentrated solution is set to 0 to-5 ℃ of deepfreeze 24h, cold preservation liquid is added to 0.3% filter aid kieselguhr, filter, filtrate reconcentration containing 3g crude drug amount, sets to 0-5 ℃ of deepfreeze 24h to every milliliter, and cold preservation liquid is filtered, and obtains medicinal liquid.
Embodiment 2
Take duck Tripterygium wilfordii 0.20kg, Rhizoma Curculiginis 0.30kg, XIANHUA Radix Stephaniae Japonicae 0.15kg, to sitting leaf 0.15kg, Radix Alangii 0.10kg and Herba Lysionoti Pauciflori 0.10kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added to water and cover powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 8 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 6 times of amounts of medical material, decoct 1h, get twice decocting liquid and merge, filter the concentrated solution that while being concentrated into 90 ℃, relative density is 1.15; Concentrated solution is set to 0 to-5 ℃ of deepfreeze 24h, cold preservation liquid is added to 0.3% filter aid kieselguhr, filter, filtrate reconcentration containing 3g crude drug amount, sets to 0-5 ℃ of deepfreeze 24h to every milliliter, and cold preservation liquid is filtered, and obtains medicinal liquid.
Embodiment 3
Take duck Tripterygium wilfordii 0.35kg, Rhizoma Curculiginis 0.15kg, XIANHUA Radix Stephaniae Japonicae 0.18kg, to sitting leaf 0.18kg, Radix Alangii 0.08kg and Herba Lysionoti Pauciflori 0.08kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added to water and cover powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 8 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 6 times of amounts of medical material, decoct 1h, get twice decocting liquid and merge, filter the concentrated solution that while being concentrated into 90 ℃, relative density is 1.15; Concentrated solution is set to 0 to-5 ℃ of deepfreeze 24h, cold preservation liquid is added to 0.3% filter aid kieselguhr, filter, filtrate reconcentration containing 3g crude drug amount, sets to 0-5 ℃ of deepfreeze 24h to every milliliter, and cold preservation liquid is filtered, and obtains medicinal liquid.
Embodiment 4
Take duck Tripterygium wilfordii 0.25kg, Rhizoma Curculiginis 0.25kg, XIANHUA Radix Stephaniae Japonicae 0.11kg, to sitting leaf 0.11kg, Radix Alangii 0.16kg and Herba Lysionoti Pauciflori 0.16kg, clean roguing, dry, pulverize; Again above-mentioned graininess medical material is added to water and cover powder 2cm, soak 1-1.2h, pull medical material out and put multi-functional extraction and decoct with water secondary in filling with, add up for the first time the water of 8 times of amounts of medical material, decoct 2h, get decocting liquid, filter, add up for the second time the water of 8 times of amounts of medical material, decoct 1h, get twice decocting liquid and merge, filter the concentrated solution that while being concentrated into 90 ℃, relative density is 1.15; Concentrated solution is set to 0 to-5 ℃ of deepfreeze 24h, cold preservation liquid is added to 0.3% filter aid kieselguhr, filter, filtrate reconcentration containing 3g crude drug amount, sets to 0-5 ℃ of deepfreeze 24h to every milliliter, and cold preservation liquid is filtered, and obtains medicinal liquid.
Clinical practice example
Chain reaction in patients with premature ovarian 49 examples, 1. clinical manifestation: occurred in the past amenorrhea for 40 years old, the time reaches more than 4 months, with perimenopausal syndrome symptoms such as mood change, paraesthesia, insomnia, hypomnesis, senile vaginitis, genital organ atrophys.2. lab testing: ovarian function: follicule-stimulating hormone (FSH) >40U/L, estradiol 73.2pmo1/L, lutropin is normal or increase.METHOD FOR CONTINUOUS DETERMINATION at least 2 times, at least 1 month, interval.Both transvaginal ultrasonography: bilateral ovaries is less, ovary is interior without dominant follicle, Continuous Observation anovulation sign, endometrium thickness <6mm, loses positive atmosphere 3rd side cut and levies.3. tcm clinical practice performance: the clinical manifestation of the ovarian hypofunction such as amenorrhea, hectic fever, sweating, vaginal dryness.31 years old-39 years old all patients' age, 35 years old mean age, the course of disease 3 years～4.5 years, average course of disease 3.6 years; According to the principle of random assortment, be divided into two groups, test group 24 examples, matched group 25 examples, the equal no significant difference of physical data such as two groups of ages, course of disease, has comparability.
Two groups all the test of row progestogen is negative.Matched group gives artificial cycle therapy for treating: Progesterone 20mg, every day 1 time, intramuscular injection, continuous 5d, drug withdrawal 3-7d, menstrual onset, menstruation the 5th day or do not have menstrual onset, drug withdrawal the 7th day, starts to take diethylstilbestrol 1mg, every day 1 time, be used in conjunction 22d, last 5d adds medroxyprogestetone acetate 10mg, every day 1 time, within 3 months, is 1 course for the treatment of.Test group patient takes Chinese medicine oral liquid of the present invention (embodiment of the present invention 1 preparation), and every day, 40mL, divided decoction being taken warmly sooner or later 2 times, within 3 months, was 1 course for the treatment of, treated 2 courses for the treatment of.By following curative effect determinate standard, add up therapeutic outcome:
Effective: menstruation rule is risen more than 1 year, hormone determination all recovers normally, the transference cures such as perimenopausal syndrome, and B ultrasonic shows that uterus and ovary are all normal.
Effective: in 1 year menstrual onset 6 times or more than, it is normal that hormonal readiness recovers, the perimenopausal syndrome symptom such as occasionally have hectic fever, sweating, dyspareunia, lose one's temper.B ultrasonic show uterus and ovary normal.
Invalid: still irregular menstruation, hormone determination follicule-stimulating hormone (FSH) >40U/L, estradiol <73.2pmol/L, B ultrasonic shows that bilateral ovaries is less, ovary is interior without dominant follicle, Continuous Observation anovulation sign, endometrium thickness <6mm, loses positive atmosphere 3rd side cut and levies.
Therapeutic outcome shows, effective 3 examples of test group, and effective 16 examples, invalid 5 examples, total effective rate is 79.2%; Effective 4 examples of matched group, effective 15 examples, invalid 6 examples, total effective rate is 76.0%.After treatment, the concrete result of the test of two groups of Clinical efficacy comparisons is in Table 1.
The Clinical efficacy comparison of table 1 test group and matched group
Claims (5)
1. a pharmaceutical composition of preventing and treating premature ovarian failure, is characterized in that: described pharmaceutical composition is extracted and is prepared from through decocting by the traditional Chinese medicinal material raw materials of following weight portion: duck Tripterygium wilfordii 20-38 part, Rhizoma Curculiginis 15-30 part, XIANHUA Radix Stephaniae Japonicae 11-18 part, to sitting leaf 11-18 part, Radix Alangii 8-16 part, Herba Lysionoti Pauciflori 8-16 part.
2. prevent and treat according to claim 1 the pharmaceutical composition of premature ovarian failure, it is characterized in that: described pharmaceutical composition is extracted and is prepared from through decocting by the traditional Chinese medicinal material raw materials of following weight portion: duck Tripterygium wilfordii 25-32 part, Rhizoma Curculiginis 20-24 part, XIANHUA Radix Stephaniae Japonicae 13-15 part, to sitting leaf 13-15 part, Radix Alangii 10-13 part, Herba Lysionoti Pauciflori 10-13 part.
3. prevent and treat according to claim 2 the pharmaceutical composition of premature ovarian failure, it is characterized in that: described pharmaceutical composition is extracted and is prepared from through decocting by the traditional Chinese medicinal material raw materials of following weight portion: 28 parts of duck Tripterygium wilfordii, 22 parts of Rhizoma Curculiginises, 14 parts of XIANHUA Radix Stephaniae Japonicaes, to sitting 14 parts, leaf, 12 parts of Radix Alangiis, 12 parts of Herba Lysionoti Paucifloris.
4. according to the pharmaceutical composition of preventing and treating premature ovarian failure described in claim 1-3 any one, it is characterized in that: described pharmaceutical composition is oral formulations.
5. the purposes of the traditional Chinese medicinal material raw materials compositions described in claim 1-3 any one in the medicine of preparation prevention premature ovarian failure.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410415513.9A CN104173620A (en) | 2014-08-21 | 2014-08-21 | Pharmaceutical composition for preventing and treating premature ovarian failure and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410415513.9A CN104173620A (en) | 2014-08-21 | 2014-08-21 | Pharmaceutical composition for preventing and treating premature ovarian failure and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104173620A true CN104173620A (en) | 2014-12-03 |
Family
ID=51955144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410415513.9A Pending CN104173620A (en) | 2014-08-21 | 2014-08-21 | Pharmaceutical composition for preventing and treating premature ovarian failure and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104173620A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105709112A (en) * | 2016-04-29 | 2016-06-29 | 张雪燕 | Pharmaceutical composition for preventing and treating premature ovarian failure as well as preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005507886A (en) * | 2001-09-21 | 2005-03-24 | メルク エンド カムパニー インコーポレーテッド | Androstanes as androgen receptor modulators |
| CN102885951A (en) * | 2011-07-18 | 2013-01-23 | 天津太平洋制药有限公司 | Medicament for treating premature ovarian failure |
-
2014
- 2014-08-21 CN CN201410415513.9A patent/CN104173620A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005507886A (en) * | 2001-09-21 | 2005-03-24 | メルク エンド カムパニー インコーポレーテッド | Androstanes as androgen receptor modulators |
| CN102885951A (en) * | 2011-07-18 | 2013-01-23 | 天津太平洋制药有限公司 | Medicament for treating premature ovarian failure |
Non-Patent Citations (2)
| Title |
|---|
| 滕秀香: "柴松岩辨证治疗卵巢早衰经验", 《中国中医药信息杂志》 * |
| 马文熙等: "《抗衰老与健康》", 30 June 2014 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105709112A (en) * | 2016-04-29 | 2016-06-29 | 张雪燕 | Pharmaceutical composition for preventing and treating premature ovarian failure as well as preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108904685A (en) | Purposes of the fritillaria total alkaloids extract in the drug or health care product of preparation prevention and treatment Hashimoto thyroiditis | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN102058847A (en) | Chinese medicine composition for treating pelvic cavity diseases as well as preparation method and application thereof | |
| CN107648468B (en) | Traditional Chinese medicine composition for treating chronic obstructive pulmonary disease and application thereof | |
| CN101966312B (en) | Chinese medicinal composition for treating chronic renal failure and preparation method thereof | |
| CN104173620A (en) | Pharmaceutical composition for preventing and treating premature ovarian failure and application thereof | |
| CN102188483B (en) | Extract for treating pharyngolaryngitis and preparation method thereof | |
| CN105796620A (en) | New applications of radix notoginseng and radix notoginseng extract to preparation of medicines for treating psoriasis | |
| CN101199771A (en) | Medicament compound for treating menopause syndrome and preparing method thereo | |
| CN103550744B (en) | A kind of pure Chinese medicinal preparation for oral ulcer | |
| CN103157048B (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammation and preparation method thereof | |
| CN104873781A (en) | Traditional Chinese medicine for treating phlegm and heat-accumulated lung type chronic bronchitis and preparation method thereof | |
| CN103800736A (en) | Pharmaceutical composition for treating hypertensive nephrosclerosis and application of pharmaceutical composition | |
| CN103479859A (en) | Traditional Chinese medicine composition for treating hyperandrogenism of polycystic ovary syndrome | |
| CN104547026A (en) | Preparation method and application of salvia miltiorrhiza leave and panax pseudo-ginseng extract | |
| CN103127358B (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method | |
| CN116211987B (en) | Traditional Chinese medicine composition for treating refractory endocrine drug-resistant breast cancer, traditional Chinese medicine preparation and application thereof | |
| CN103655586B (en) | Medicagenic acid-3-O-β-D-Glucose glycosides prevents and treats the application in osteopathia medicine in preparation | |
| CN102258583A (en) | Traditional Chinese medicine preparation for treating chronic and nonspecific ulcerative colitis and preparation method thereof | |
| CN106668601B (en) | Traditional Chinese medicine composition for treating cerebrovascular disease phlegm-heat syndrome and preparation method and application thereof | |
| CN106177413A (en) | A kind of granule for treating pharyngitis | |
| CN105168397A (en) | Medicine composition for preventing and treating nephrosis | |
| CN104524144A (en) | Traditional Chinese medicine for treating uroschesis | |
| CN105381410A (en) | Traditional Chinese medicinal preparation for treating hepatitis | |
| CN104524143A (en) | Traditional Chinese medicine for treating uroschesis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141203 |
|
| RJ01 | Rejection of invention patent application after publication |